Showing results (201-210 of 454) with videos related to
Sort By:
Pageof 46
Frontiers in Immunology|May 8, 2023
The magic of small-molecule drugs during <i>ex vivo</i> expansion in adoptive cell therapyHanwen Zhang, Tenzin Passang, Sruthi Ravindranathan, et al.Stem Cells (Dayton, Ohio)|June 15, 2016
Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFNγ LicensingRaghavan Chinnadurai, Ian B Copland, Marco A Garcia, et al.Leukemia & Lymphoma|April 28, 2000
High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphomaS Lonial, T W Jones, S Devine, et al.Journal of Palliative Medicine|May 1, 2015
Place of Death among Hospitalized Patients with Cancer at the End of LifeSusannah K Wallace, Dorothy K Waller, Barbara C Tilley, et al.Experimental Hematology|September 13, 2002
The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantationMichael W Schuster, Roy Beveridge, Debra Frei-Lahr, et al.Cytotherapy|June 19, 2022
Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturingMuna Qayed, Joseph P McGuirk, G Doug Myers, et al.Leukemia & Lymphoma|September 18, 2012
The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation studyJulie M Vose, Jonathan W Friedberg, Edmund K Waller, et al.Leukemia & Lymphoma|August 8, 2017
Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemiaVishal Dhere, Scott Edelman, Edmund K Waller, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 22, 2003
Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effectsCynthia R Giver, Richard O Montes, Stephen Mittelstaedt, et al.Plos One|June 1, 2013
VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected miceJian-Ming Li, Kasia A Darlak, Lauren Southerland, et al.Pageof 46